<DOC>
	<DOCNO>NCT00608777</DOCNO>
	<brief_summary>The purpose study determine calcipotriene/bethamethasone safely effectively manage occurence LMB ( mild localize breakthrough ) patient recieving efalizumab ( Raptiva ) moderate severe plaque psoriasis . It hypothesize calcipotriene/betamethasone ( Taclonex ) could use manage LMB thus allow patient continue efalizumab without interruption .</brief_summary>
	<brief_title>Effect Topical Calcipotriene/Betamethasone ( Taclonex ) Managing Localized Breakthrough Moderate Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva )</brief_title>
	<detailed_description>LMB ( localize mild breakthrough ) one two psoriasis adverse event commonly see efalizumab treat patient . It generally papular nature involve exist lesion . Clinical experience suggest LMB may clinical impact patient respond efalizumab therefore may treat without interrupt efalizumab therapy . To relieve discomfort topical therapy may indicate symptom resolve . This single arm , open label study . Fifteen patient receive efalizumab entrance study develop LMB wil enrol . Topical calcipotriene/betamethasone ( Taclonex ) apply area ( except face , axillae groin ) day two week . The PI may choose continue two week need total four week therapy . All patient continue efalizumab without dose modification duration study . Patients return follow visit week 2 , 4 6 . Topical desonide may use LMB involvement face , groin axilla .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Ability provide write , informed consent comply study assessment full duration study . Age 18 year old . Moderate severe plaque psoriasis treat efalizumab . Develop LMB efalizumab treatment . PGA LMB least mild ( 2 ) exclude face , axillae groin . Patients know hypersensitivity efalizumab , calcipotriene/betamethasone component . Pregnant lactating woman . Known suspect disorder calcium metabolism . Erythrodermic , exfoliative and/or pustular psoriasis . Concomitant use topical thaerapy , phototherapy immunosuppressive agent . LMB ( area face , axillae groin ) constitute 30 % total body surface area . Patients generalized inflammatory flare define widespread worsen psoriasis characterize erythematous edematous lesion within exisiting plaque . Any condition investigator believe would pose significant hazard subject investigational therapy initiate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Localized mild breakthrough</keyword>
</DOC>